Johnson & Johnson Expands Work in Infectious Diseases

October 21, 2010

Johnson & Johnson plans to expand its work in infectious diseases such as HIV, hepatitis C and the flu, *The Wall Street Journal* reports. Sheri McCoy, who heads the company's pharmaceuticals business, made that assertion during a presentation to investors of 2010 third-quarter earnings. The company already sells HIV drugs such as Prezista and Intelence through Tibotec, a pharmaceutical company it acquired in 2002. Johnson & Johnson has high hopes for telaprevir, a promising hep C treatment, being developed with Vertex Pharmaceuticals. It also has agreed to acquire Crucell, a vaccine maker.

To read the *Journal* article, click here.

© 2026 Smart + Strong All Rights Reserved.

http://beta.docker.poz.com/article/Johnson-Johnson-HIV-19279-9841